Journal of Cancer Research and Practice 5 (2018) 9-12

Contents lists available at ScienceDirect



Journal of Cancer Research and Practice

journal homepage: http://www.journals.elsevier.com/journal-of-cancerresearch-and-practice

Original Article

Low-stage pediatric neuroblastoma: A 20-year single institution review



Paul C.Y. Chang ^{a, b}, Nien-Lu Wang ^a, Hsi-Che Liu ^{b, c}, Der-Cherng Liang ^{b, c}, Ting-Chi Yeh ^{b, c}, Jen-Yin Hou ^{b, c}, Jin-Cherng Sheu ^{a, *}

^a Division of Pediatric Surgery, Mackay Memorial Hospital, Taipei, Taiwan

^b Department of Medicine, Mackay Medical College, New Taipei City, Taiwan

^c Division of Pediatric Hematology–Oncology, Mackay Memorial Hospital, Taipei, Taiwan

ARTICLE INFO

Article history: Received 12 September 2017 Received in revised form 20 November 2017 Accepted 21 November 2017 Available online 24 November 2017

Keywords: Chemotherapy Neuroblastoma Pediatric tumors Surgery Survival rate

ABSTRACT

Background: Neuroblastoma is a common childhood cancer with poor prognosis. This is a retrospective review of the outcomes in children with low-stage neuroblastoma in Taiwan.

Methods: We reviewed the charts of all children with International Neuroblastoma Staging System (INSS) stages 1 and 2 diagnosed at the Mackay Memorial Hospital between November 1994–December 2013. The patients' demographic data, age of diagnosis, treatment, and survival rates were analyzed.

Results: A total of 75 children with all stages of neuroblastoma were identified, of which 23 children in the low stage were enrolled. There were 12 (16.0%) patients in stage 1, and 11 (14.6%) patients in stage 2. The mean age of diagnosis for stage 1 and stage 2 was 5.4 months and 10.2 months, respectively. A total of 18 (78.3%) patients received initial complete surgical excision, and 5 patients received initial biopsy. The site of the tumor was the adrenal gland in 19 (82.6%) patients. Total or near-total resection was possible in 18 (78.3%) patients; all children with stage 1 were treated by complete surgical resection. Seven patients (63.6%) in stage 2 received chemotherapy. Children in both stages 1 and 2 had the same 5-year overall survival of 100%. The event-free survival rate for patients in stage 1 and stage 2 was 91.7% and 81.8%, respectively.

Conclusion: This retrospective study confirmed that children with stage 1 and 2 neuroblastoma had good outcomes. Specifically, children with stage 1 disease are best treated by surgery alone, but selected patients in stage 2 need additional chemotherapy.

© 2018 Taiwan Oncology Society. Publishing services by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction

Neuroblastoma is the third most common cancer in children under one year of age. In fact, it is the most common extracranial solid tumor in childhood,¹ and most commonly found in the retroperitoneal cavity. The incidence of neuroblastoma is about 10 cases per million in children under 15 years of age.^{2,3} It accounts for 10–15% of all pediatric cancer fatalities⁴; the overall 5-year survival rate is poor, at less than 50%.⁵ However, patients with low-stage disease typically have excellent outcomes.⁶ The purpose of this study was to evaluate the clinical characteristics and treatment

* Corresponding author. Division of Pediatric Surgery, Mackay Memorial Hospital, 92, Sec.2 Chung-Shan North Road, Taipei, Taiwan.

E-mail address: jc.sheu@msa.hinet.net (J.-C. Sheu). Peer review under responsibility of Taiwan Oncology Society. outcomes of children with stages 1 and 2 neuroblastoma from a single institution in Taiwan.

2. Methods

This was a retrospective study involving all children who were diagnosed with stage 1 and 2 neuroblastoma between November 1994 and December 2013 at the Mackay Memorial Hospital in Taipei, Taiwan. After being approved by the Institutional Review Board, medical records of the children were analyzed. The demographic data, age of diagnosis, surgery, treatment, radiological and laboratory data, and survival outcomes were recorded. Diagnosis was made from biopsy specimens from the primary or metastatic site, or bone marrow biopsy. The location of the primary tumor was based on computed tomography (CT) findings and/or confirmed in surgery. The diagnosis and staging assessments were made according to the International Neuroblastoma Staging System

https://doi.org/10.1016/j.jcrpr.2017.11.003

2311-3006/© 2018 Taiwan Oncology Society. Publishing services by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/ licenses/by-nc-nd/4.0/). (INSS). Patients were treated according to their assigned risk group (low, intermediate and high risk) and according to the protocols of the Taiwan Pediatric Oncology Group (TPOG). Written informed consent was obtained from all patients prior to chemotherapy.

3. Statistical analysis

Event-free survival (EFS) was measured from the date of diagnosis to the date of progression or relapse, or patient death. Overall survival (OS) was calculated from the date of diagnosis until the date of death, or the date of last follow-up. The final outcomes were overall survival (OS) and event-free survival (EFS). Analysis of 5year OS and EFS were performed using the Kaplan-Meier method and the log-rank test of significance.

4. Results

A total of 75 children with all stages of neuroblastoma were identified, of which 23 children in the low stage were enrolled. There were 12 (16.0%) patients in stage 1, and 11 (14.6%) patients in stage 2. The demographic data was summarized in Table 1. The median follow-up was 13.6 years (range 2.5–19.6 years). There were 8 (34.8%) patients who were under 1 year of age. A total of 18 (78.3%) patients received initial surgical excision, and 5 patients received initial biopsy.

4.1. Stage 1

There were 12 (16.0%) patients in stage 1, with a mean age of diagnosis of 5.4 months (range 0–26.3 months). All children with stage 1 were treated by surgery alone, and total excision was possible in all patients. There was 1 patient who suffered a relapse at 6.1 month of age. However, the patient received salvage chemotherapy and thereafter had long-term disease-free survival.

4.2. Stage 2

There were 11 (14.6%) patients in stage 2, with a median age of diagnosis of 10.2 months (range 0.3–21.1 months). Five patients received initial open surgical biopsy, followed by chemotherapy. Six patients received up-front total or near-total excision, followed by adjuvant chemotherapy, which included carboplatin, etoposide, cyclophosphamide, and doxorubicin. One patient had MYCN

Table 1

Clinical	characteristics	of all	patients	with	stage	1	and	stage	2	neuroblastoma
(n = 23)).									

Variable	Stage 1	Stage 2
Age at diagnosis, (months)		
Mean	5.4	10.2
Range	0-26.3	0.3-21.1
\leq 1 year, n (%)	5 (41.7%)	3 (27.3%)
>1 year, n (%)	7 (58.3%)	8 (72.7%)
Sex, n (%)		
Male	5 (41.7%)	6 (54.5%)
Female	7 (58.3%)	5 (45.5%)
INSS stage, n (%)	12 (15.4%)	11 (14.1%)
Primary tumor site, n (%)		
Adrenal	11 (91.7%)	8 (72.7%)
Extra-adrenal	1 (8.3%)	3 (27.3%)
Surgery, n (%)		
Initial biopsy only	0 (0%)	5 (45.5%)
Initial excision	12 (100%)	2 (18.2%)
Total		
Near total	0 (0%)	4 (36.4%)
Chemotherapy	0 (0%)	7 (63.6%)

amplification, and 2 patients had unfavorable Shimada histology. Seven patients (63.6%) in stage 2 received chemotherapy. There were 2 relapses, at 7.6, and 13.2 months after diagnosis, respectively. The first patient was an 11.7-month-old boy, who had stroma-poor, undifferentiated histology with high mitosiskaryorrhexis index (MKI). The second patient was a 19.1-monthold boy, who had a similar histology, and amplified MYCN oncogene.

5. Survival analysis

All children with stages 1 and 2 were alive at 5 years. The 5-year OS and EFS for stage 1 were 100% and 91.7%, respectively. The 5-year OS and EFS for stage 2 were 100% and 81.8%, respectively (Fig. 1). Both groups of patients older and younger than one year of age had OS of 100%. The 5-year EFS for patients under and over 1 year of age were 95.7% and 91.3%, respectively. (Fig. 2). Results using the log-rank test were not significant.

6. Discussion

This is a 20-year retrospective review which provided information on clinical and outcome analysis in Taiwanese children with low-stage neuroblastoma. All children with stages 1 and 2 disease had good prognosis and were all alive at the 5- year follow-up. All



Fig. 1. Survival outcome in patients with stage 1 and stage 2 neuroblastoma (n = 23). Upper graph: overall survival. Lower graph: event-free survival.



Fig. 2. Survival outcome in patients with age over and under one year of age (n = 23). Upper graph: overall survival. Lower graph: event-free survival.

patients in stage 1 received surgery alone. This result is comparable to current international results, which range from 95 to 99% survival rate.^{4,5} Two factors may have contributed to this result, namely, a multi-disciplinary team approach, and a dedicated pediatric oncological surgeon.

Age is an important prognostic indicator in patients with neuroblastoma.⁶ The percentage of patients in our cohort under 1 year of age (29.5%) was similar to that range among the reported series of between 22 and 38%.^{7–9} It appears that the higher percentage of infants in a cohort may contribute to better outcomes. We postulate that one of the most important factors that affected outcome was due to the universal coverage (98%) of the population by the generally available National Health Insurance in Taiwan.¹⁰ Utilization of prenatal services has increased since the introduction of Taiwan's National Health Insurance in 1995.¹¹ Patients have easy access to most clinics and hospitals, with only a short waiting time and a very small required co-payment. This ease of access and lack of barriers to care in turn have resulted in early detection, diagnosis and treatment.

Surgical resection alone has become the therapy of choice for low-risk neuroblastoma.^{12,13} De Bernadi et al.¹⁴ showed that complete or partial resection of neuroblastoma cured most of the stage 1 patients, and selected stage 2 patients as well. In our cohort, the primary resection rate was 74%, primarily in those patients under 1 year of age. However, in high risk patients, the value of completing resection remains controversial.^{15–17} The most important constant factor in our cohort was that 95% of all operations were performed by the same senior surgeon (JCS).

Nonetheless, there were several limitations to this study. First, the retrospective nature of this study limited our scope with regards to discussions and analyses made during the multidisciplinary conferences. Efforts were made to access written and electronic records of the decision-making process, in order to obtain the most accurate results. Second, over the 20-year record review period, there has been an evolution of understanding of the disease with regards to staging and risk-based therapy, as well as more advanced myeloablative chemotherapy and stem cell transplantation therapy.¹⁸ This may have affected risk stratification and treatment protocol. However, a recent Taiwanese publication noted minimal change in OS and EFS between newer and older chemotherapy regimen.¹⁹ Third, due to resource availability, MYCN oncogene status was not routinely performed in the earlier era of this review. This is an important parameter for risk stratification and provides an important prognostic factor, but mainly for pa-tients with higher stage disease.^{20–22} On the other hand, Bagatell et al.²³ reported that MYCN amplification did not statistically affect outcome in patients with stages 1 and 2 disease.

7. Conclusion

In this long-term retrospective review, we noted that 1/3 of our patients with neuroblastoma presented at stages 1 and 2. Our retrospective review showed excellent overall and event-free survival rates in comparison to other international series studies. The outcome for patients with stage 1, stage 2, and those under one year of age was excellent. Considerable effort should be made to confirm MYCN status in all of our patients, in order to identify any subgroup of patients with poor prognosis and apply additional advanced therapy.

Conflict of interest

The authors declare no conflicts of interest in this study.

References

- Louis CU, Shohet JM. Neuroblastoma: molecular pathogenesis and therapy. Annu Rev Med. 2015;66:49–63.
- Matthay KK, George RE, Yu AL. Promising therapeutic targets in neuroblastoma. Clin Cancer Res. 2012;18:2740–2753.
- Liu YL, Lo WC, Chiang CJ, et al. Incidence of cancer in children aged 0–14 years in Taiwan, 1996–2010. *Cancer Epidemiol*. 2015;39:21–28.
- Pinto NR, Applebaum MA, Volchenboum SL, et al. Advances in risk classification and treatment strategies for neuroblastoma. J Clin Oncol. 2015;33:3008–3017.
- 5. Smith MA, Altekruse SF, Adamson PC, et al. Declining childhood and adolescent cancer mortality. *Cancer*. 2014;120:2497–2506.
- Maris JM. Recent advances in neuroblastoma. N Engl J Med. 2010;362: 2202–2211.
- El-Sayed MI, Ali AM, Sayed HA, Zaky EM. Treatment results and prognostic factors of pediatric neuroblastoma: a retrospective study. *Int Arch Med.* 2010;3: 37–45.
- London WB, Castleberry RP, Matthay KK, et al. Evidence for an age cutoff greater than 365 days for neuroblastoma risk group stratification in the Children's Oncology Group. J Clin Oncol. 2005;23:6459–6465.
- Cotterill SJ, Pearson AD, Pritchard J, et al. Clinical prognostic factors in 1277 patients with neuroblastoma: results of The European Neuroblastoma Study Group 'Survey' 1982-1992. Eur J Cancer. 2000;36:901–908.
- Lee YC, Huang YT, Tsai YW, et al. The impact of universal National Health Insurance on population health: the experience of Taiwan. *BMC Health Serv Res.* 2010;10:225–233.
- Chen LM, Wen SW, Li CY. The impact of national health insurance on the utilization of health care services by pregnant women: the case in Taiwan. *Matern Child Health J.* 2001;5:35–42.
- 12. Perez CA, Matthay KK, Atkinson JB, et al. Biologic variables in the outcome of stages I and II neuroblastoma treated with surgery as primary therapy: a children's cancer group study. *J Clin Oncol.* 2000;18:18–26.
- Strother DR, London WB, Schmidt ML, et al. Outcome after surgery alone or with restricted use of chemotherapy for patients with low-risk neuroblastoma: results of Children's Oncology Group study P9641. J Clin Oncol. 2012;30: 1842–1848.
- 14. De Bernardi B, Mosseri V, Rubie H, et al. Treatment of localised resectable

neuroblastoma: results of the LNESG1 study by the SIOP Europe Neuroblastoma Group. *Br J Cancer*. 2008;99:1027–1033.
15. Koh CC, Sheu JC, Liang DC, Chen SH, Liu HC. Complete surgical resection plus

- Koh CC, Sheu JC, Liang DC, Chen SH, Liu HC. Complete surgical resection plus chemotherapy prolongs survival in children with stage 4 neuroblastoma. *Pediatr Surg Int.* 2005;21:69–72.
- 16. Simon T, Haberle B, Hero B, et al. Role of surgery in the treatment of patients with stage 4 neuroblastoma age 18 months or older at diagnosis. *Clin Oncol.* 2013;31:752–758.
- Englum BR, Rialon KL, Speicher PJ, et al. Value of surgical resection in children with high-risk neuroblastoma. *Pediatr Blood Cancer*. 2015;62:1529–1535.
 Berthold F, Boos J, Burdach S, et al. Myeloablative megatherapy with autolo-
- Berthold F, Boos J, Burdach S, et al. Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomised controlled trial. *Lancet Oncol.* 2005;6:649–658.
- 19. Chang HH, Liu YL, Lu MY, et al. A multidisciplinary team care approach

improves outcomes in high-risk pediatric neuroblastoma patients. *Oncotarget*. 2017;17:4360–4372.

- 20. Seeger RC, Brodeur GM, Sather H, et al. Association of multiple copies of the Nmyc oncogene with rapid progression of neuroblastomas. *N Engl J Med.* 1985;313:1111–1116.
- Matthay KK, Perez C, Seeger RC, et al. Successful treatment of stage III neuroblastoma based on prospective biologic staging: a Children's Cancer Group study. *J Clin Oncol.* 1998;16:1256–1264.
 Park JR, Villablanca JG, London WB, et al. Outcome of high-risk stage 3 neu-
- Park JR, Villablanca JG, London WB, et al. Outcome of high-risk stage 3 neuroblastoma with myeloablative therapy and 13-cis-retinoic acid: a report from the Children's Oncology Group. *Pediatr Blood Cancer*. 2009;52:44–50.
- 23. Bagatell R, Beck-Popovic M, London WB, et al. Significance of MYCN amplification in international neuroblastoma staging system stage 1 and 2 neuroblastoma: a report from the international neuroblastoma risk group database. *J Clin Oncol.* 2009;27:365–370.